Delay in OnabotulinumtoxinA Treatment During the COVID-19 Pandemic-Perspectives from a Virus Hotspot
Recommended Citation
Ali A. Delay in OnabotulinumtoxinA Treatment During the COVID-19 Pandemic-Perspectives from a Virus Hotspot. Headache 2020; 60(6):1183-1186.
Document Type
Article
Publication Date
6-1-2020
Publication Title
Headache
Abstract
The COVID-19 pandemic has undoubtedly changed our practice of medicine. With our collective resources and attention focused on caring for those afflicted with the disease, other medical conditions have temporarily but understandably faced constraint. For migraine patients who often require in-person visits for infusions and procedures, this has become particularly challenging. Here, we share our experience in navigating this exigency amidst a local surge of COVID-19.
Medical Subject Headings
Adult; Betacoronavirus; Botulinum Toxins, Type A; Coronavirus Infections; Female; Humans; Middle Aged; Migraine Disorders; Pandemics; Pneumonia, Viral; Time-to-Treatment; Treatment Outcome
PubMed ID
32359098
Volume
60
Issue
6
First Page
1183
Last Page
1186
